Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.75 - $5.32
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.34M
Enterprise Value$12.56M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap5.37
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Proprietary EP Mapping CatheterCatheter Precision’s core proprietary electrophysiology mapping catheter targets cardiac ablation procedures, a durable clinical use-case. A device tied to procedure workflows supports recurring, per-procedure revenue and creates clinical adoption and reimbursement friction that can sustain sales over months to years.
Rapid Revenue Growth Off Early BaseTTM revenue growth from a low base indicates early commercial traction and expanding market penetration. Persistent top-line expansion, if sustained, can validate product-market fit and supports step-up in fixed-cost absorption, improving long-term margins as scale is achieved.
Recent Capital Injection Provides RunwayA $3.47M preferred-stock raise materially extends near-term liquidity, giving management time to pursue commercialization and regulatory milestones. While dilutive in structure, the funding reduces immediate financing pressure and enables execution on product adoption and clinical studies over the coming months.
Bears Say
Sustained Negative Cash FlowMulti-year negative operating cash flow and FCF around -$8.7M to -$8.8M show the business is burning cash faster than it generates it. This structural cash deficit forces repeated external financing, constrains strategic choices, and risks underinvestment or dilution if growth stalls.
Deep Operating Losses And Weak MarginsExtremely negative EBIT and net margins reflect a cost base far exceeding current revenue. Unless the company meaningfully scales revenue or materially cuts costs, losses will persist, undermining long-term profitability and making sustained cash generation unlikely without substantial structural change.
High Dependence On External FinancingFrequent use of convertible preferred financings, equity consideration for acquisitions, and authorization for reverse splits indicate ongoing reliance on capital markets. This creates dilution, complex capitalization, and governance risks that can impede long-term investor support and strategic stability.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.75 and its highest was $5.32 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.34M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 53 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 2,692,473 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
Technical Analysis
Ownership Overview
0.52%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---